Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ligelizumab extension study in chronic spontaneous urticaria
NL-OMON52548Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, double-blind trial of ligelizumab in chronic idiopathic urticaria (CIU) (2 arms), sponsored by Novartis. Primary endpoint: Efficacy of retreatment with ligelizumab 72 mg or 120 mg every 4 weeks. Started Aug 2020; status: active, not recruiting.
02
Drugs
ligelizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on NL-OMON52548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52548.